psychiatric « Science and Enterprise

Low-Dose Oral Film Reduces Mental Disorder Agitation

By Alan, on May 25th, 2023%

Interim results from a clinical trial show a drug given as a dissolvable oral film in a lower dose reduces agitation in people with bipolar disorder and schizophrenia. . . . → Read More: Low-Dose Oral Film Reduces Mental Disorder Agitation

Safer Forms of Psilocybin Assessed in Preclinical Study

By Alan, on May 22nd, 2023%

A biotechnology company says it identified engineered precursors of a psychedelic compound that in lab animals produce safe and intended therapeutic effects. . . . → Read More: Safer Forms of Psilocybin Assessed in Preclinical Study

Infographic – Psychedelics Funding Coming Down

By Alan, on May 6th, 2023%

Bar chart: Venture funding in psychedelics, 2019-2023

Technology intelligence company CB Insights says this week that psychedelic therapies and services are generating little interest among venture investors this year, with only nine deals totaling $21 million. . . . → Read More: Infographic – Psychedelics Funding Coming Down

Trial Underway Testing Psychedelic Drug for Depression

By Alan, on May 4th, 2023%

The first participant in a clinical trial received a dose of a psychedelic therapy, assessing the experimental compound in people with treatment resistant depression. . . . → Read More: Trial Underway Testing Psychedelic Drug for Depression

Trial to Test Low-Dose Psilocybin for Mental Distress

By Alan, on March 21st, 2023%

A developer of mental health therapies from psychedelic compounds says it received FDA clearance for a clinical trial testing low doses of psilocybin. . . . → Read More: Trial to Test Low-Dose Psilocybin for Mental Distress

Standard Electronic Biomarkers Validated for Schizophrenia

By Alan, on March 17th, 2023%

A new study validates standard electronic instrument measures of healthy individuals and people with schizophrenia to enable reliable clinical trials for treating the disease. . . . → Read More: Standard Electronic Biomarkers Validated for Schizophrenia

Trial Testing VR to Relieve Cancer Patient Distress

By Alan, on March 7th, 2023%

A clinical trial is underway assessing virtual reality interventions for relieving distress and improve the quality of life for cancer patients receiving bone marrow transplants. . . . → Read More: Trial Testing VR to Relieve Cancer Patient Distress

Technology Showcased to Ease Mental Health Interventions

By Alan, on March 4th, 2023%

Mary Czerwinski at AAAS meeting, 4 Mar. 2023

A group of industry and academic researchers at a scientific meeting displayed advances in technology to improve access to therapy for people with mental disorders. . . . → Read More: Technology Showcased to Ease Mental Health Interventions

Psychoactive Drug Start-Up Raises $40M in Early Funds

By Alan, on February 23rd, 2023%

A new company is underway developing drugs to treat PTSD and other disorders with psychoactive compounds claimed to be safer than current psychedelics. . . . → Read More: Psychoactive Drug Start-Up Raises $40M in Early Funds

Psychedelic Drug Shown to Relieve PTSD Brain Signals

By Alan, on January 20th, 2023%

A small clinical trial shows psychotherapy with the psychedelic drug MDMA generates brain signals that help relieve symptoms in people with post-traumatic stress disorder. . . . → Read More: Psychedelic Drug Shown to Relieve PTSD Brain Signals

Subscribe for email alerts

Donate to Science & Enterprise

Like us on Facebook

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Specials

Guest Posts

Please share Science & Enterprise